Updated results to be presented at ASH in December

Our portfolio company Nordic Nanovector will present updated…
November 7, 2017/by Elisabeth K. Andersen

Zelluna Immunotherapy appoints Miguel Forte as CEO

Our portfolio company Zelluna Immunotherapy has appointed Miguel…
November 7, 2017/by Elisabeth K. Andersen

Ultimovacs henter inn 125 millioner

Vårt porteføljeselskap Ultimovacs sikrer finansiering til…
October 24, 2017/by Elisabeth K. Andersen

Targovax reports 100 % one year survival rate from trial

Our portfolio company Targovax announces encouraging one-year…
October 12, 2017/by Elisabeth K. Andersen

Kronikk i Aftenposten

Sent i september hadde Jónas Einarsson en kronikk i Aftenposten…
October 11, 2017/by Elisabeth K. Andersen

Targovax granted two US patents in short time

Our portfolio company Targovax has over the short time span of…
October 5, 2017/by Elisabeth K. Andersen

PCI Biotech receives US Orphan Drug Designation

The U.S. Food and Drug Administration (FDA) has granted Orphan…
October 5, 2017/by Elisabeth K. Andersen

View video´s from our events @ Oslo Innovation Week

Radforsk co-hosted three cancer-related events during Oslo Innovation…
October 5, 2017/by Elisabeth K. Andersen

PCI Biotech progressing positively

The progress especially applies for the fimaCHEM programme , with early promising signs of effect in Phase I in treatment of bilde duct cancer.
August 30, 2017/by Elisabeth K. Andersen

Targovax positioned for important clinical read outs

Reports significant progress, both financially and clinically, in second half 2017 report.
August 24, 2017/by Elisabeth K. Andersen

Come learn more about cancer

We arrange three seminars during Oslo Innovation Week and Forskningsdagene.
August 23, 2017/by Elisabeth K. Andersen

Photocure with revenue growth of 55% in the US

Q2 report shows significant progress in the US market
August 23, 2017/by Elisabeth K. Andersen